Illumina News and Research

RSS

Trial of non-invasive prenatal test to determine Down syndrome successful

At the moment, the only reliable way of diagnosing chromosomal irregularities during pregnancy is to use invasive prenatal methods. This causes miscarriage in about one per cent of these risky surgical procedures.

14 Apr 2011

UC researchers sequence individual glioblastoma genomes and track abnormalities through the bloodstream

Medical scientists know this about glioblastoma multiforme: the malignant brain tumor is aggressive, it is elusive, and it appears in different permutations.

5 Apr 2011

Clontech launches new SMARTer Ultra Low RNA Kit

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.

31 Mar 2011

Illumina prices 0.25% Convertible Senior Notes due 2016

Illumina, Inc. today announced the pricing of $800 million principal amount of 0.25% Convertible Senior Notes due 2016 through offerings to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

From Illumina, Inc. 15 Mar 2011

Scientists sequence Clostridium botulinum genome that produces neurotoxin

Scientists on the Norwich Research Park have sequenced the genome of a novel strain of Clostridium botulinum, one of the most dangerous pathogens known to man. The strain produces an unusual botulinum neurotoxin, known as type A5 neurotoxin, which was isolated by the Health Protection Agency, following a case of wound botulism.

8 Mar 2011

Scientists discover SNPs linked with high risk of sick sinus syndrome

Scientists at deCODE genetics and academic colleagues from Iceland, The Netherlands, Denmark, USA and Illumina, Inc., today report the discovery of single-letter variants in the sequence of the human genome associated with high risk of sick sinus syndrome.

6 Mar 2011

Accelrys releases Pipeline Pilot NGS Collection at Molecular Medicine Tri-Conference

Accelrys, Inc. (NASDAQ:ACCL), the leading scientific informatics software and services company, today announced at the Molecular Medicine Tri-Conference its entrance in the rapidly growing next generation sequencing (NGS) market with the release of the NGS Collection for Pipeline Pilot.

24 Feb 2011

Macrogen announces formation of Axeq Technologies in the US, Europe and Asia

Macrogen, Inc announces the formation of Axeq Technologies, a US-based division with operations and offices in the US, Europe and Asia. "Axeq" is a premium brand representing a whole new experience and industry-leading standards in DNA sequencing service.

22 Feb 2011

Eurofins MWG Operon's LPE libraries offer most efficient way to sequence and scaffold genomes

Eurofins MWG Operon, an expert in next generation sequencing routinely uses up to 5 different non-cloned genomic DNA libraries for sequencing with Roche GS FLX or Illumina HiSeq 2000 technology.

15 Feb 2011

CLC bio releases Version 4.5 of CLC Genomics Workbench

Today, CLC bio announced the release of CLC bio's premier desktop software package for working with genomics, transcriptomics, and epigenomics: Version 4.5 of CLC Genomics Workbench - an update which gives molecular biologists access to analyze high-througput sequencing datasets with powerful bioinformatics algorithms through a user-friendly graphical user-interface.

4 Feb 2011

New England Biolabs expands line of reagents for sample preparation

New England Biolabs has expanded its line of reagents for sample preparation upstream of next generation sequencing to include NEBNext® Small RNA Sample Prep Set 1 for sequencing on the Illumina® platforms, and NEBNext Small RNA Sample Prep Set 3 for sequencing on LIFE's SOLiD™ platform. These new products offer a new and unique protocol, which results in higher yields and lower adaptor-dimer formation, as compared to other protocols.

From New England Biolabs 3 Feb 2011

Agilent introduces first commercial RNA target enrichment system

Agilent Technologies, Inc., today introduced SureSelect RNA Capture Kits, the first commercial RNA target enrichment system enabling geneticists to focus on specific genomic loci or transcripts of research interest. The RNA capture kits make it possible to precisely measure expression levels of genes of interest and detect allelic-specific expression, splicing events and gene fusions.

3 Feb 2011

EA sponsors research grant to investigate specific cancers and kinase mutations

Expression Analysis today announced a jointly sponsored research grant for up to eight American Cancer Society Grantees to investigate and draw parallels between specific cancers and recurring mutations in specific kinases, using targeted genome sequencing.

2 Feb 2011

Tufts University calls for strategic approach to teach genomic testing in medical school

Genetics in Medicine, the official journal of the American College of Medical Genetics, published this month a paper by Tufts University faculty calling for a moderate, strategic approach to teaching personalized genomic testing in medical school curricula.

25 Jan 2011

DNAVision purchases 4 of Life Technologies' NGS platforms

DNAVision, one of European leading genetic analysis service providers, is pleased to announce the purchase of four next-generation sequencing platforms from Life Technologies, including two latest 5500xl SOLiD™ Systems.

13 Jan 2011

Illumina announces acquisition of Epicentre Biotechnologies

Illumina, today announced that it has acquired Epicentre Biotechnologies, a leading provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications.

From Illumina, Inc. 12 Jan 2011

Illumina announces next generation of iSelect custom genotyping products

Illumina, Inc. today announced its next generation of iSelect custom genotyping products that allow researchers to design custom arrays containing from 3,000 up to 1,000,000 markers, with the flexibility to add supplemental content to their array designs.

From Illumina, Inc. 10 Jan 2011

Sequenom CMM authorizes SensiGene T21 LDT clinical validation study

Sequenom, Inc. today announced that the company's wholly-owned reference laboratory, the Sequenom Center for Molecular Medicine (Sequenom CMM), has authorized commencement of a pivotal clinical validation study. This validation study is designed to evaluate the clinical performance of the SensiGene T21 Laboratory Developed Test (LDT) for the detection of an overabundance in maternal blood of chromosome 21, which is associated with fetal chromosome 21 aneuploidy.

23 Dec 2010

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

The day when an ovarian cancer patient can treat her tumor with a single, painless pill instead of a toxic drug cocktail is the ultimate goal of the pioneering research of a University of Houston scientist.

22 Dec 2010

Court dismisses Illumina's patent infringement lawsuits against Affymetrix

Affymetrix, Inc. today announced that the U.S. District Court for the Western District of Wisconsin (the "Court") has granted the company's motion for summary judgment that Affymetrix does not infringe the patents held by Illumina, Inc., and has directed that the patent infringement lawsuits brought against the company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020 be dismissed and the cases closed.

From Illumina, Inc. 15 Dec 2010